Skip to main content
. 2012 Nov 20;135(11):3336–3347. doi: 10.1093/brain/aws250

Figure 2.

Figure 2

S100B levels in CSF and serum of patients with Parkinson’s disease. In the immunoassay, significantly higher S100B levels are detectable in CSF of 84 patients with Parkinson’s disease (PD) compared with 62 neurodegeneratively healthy subjects (HC) (A). The area under the curve (AUC) equals 0.76, indicating a moderate accuracy of the parameter in differentiating the groups (B). CSF S100B levels of patients with Parkinson’s disease and healthy subjects tend to be higher with higher age (C). In serum, S100B levels do not significantly differentiate between Parkinson’s disease and healthy subjects (D). Note also the substantially lower S100B levels in serum compared with CSF (A and D).